4,768
Views
40
CrossRef citations to date
0
Altmetric
Research Paper

Ropivacaine inhibits the proliferation and migration of colorectal cancer cells through ITGB1

& ORCID Icon
Pages 44-53 | Received 04 Sep 2020, Accepted 24 Nov 2020, Published online: 21 Dec 2020

Figures & data

Figure 1. Ropivacaine inhibits the proliferation and migration of HCT116 and SW620 cells, and the invasion ability. (a). SW620 and different doses of ropivacaine after treatment, and the results of MTT detection were expressed by absorbance values at 562 nm; (b). HCT116 and different doses of ropivacaine after treatment, the results of MTT detection were expressed by absorbance values at 562 nm; (c). The result of nuclear staining of two colon cancer cells treated with different doses by DAPI; (d). Changes in cell migration within 24 h; (e). Transwell experiment results; (f). Quantitative statistical results of cell migration experiments; G. Transwell experiment to quantify statistical results. ‘*’ indicates a significant difference compared with the control group (P < 0.05). ‘**’ indicates a significant difference (P < 0.01), the same below

Figure 1. Ropivacaine inhibits the proliferation and migration of HCT116 and SW620 cells, and the invasion ability. (a). SW620 and different doses of ropivacaine after treatment, and the results of MTT detection were expressed by absorbance values at 562 nm; (b). HCT116 and different doses of ropivacaine after treatment, the results of MTT detection were expressed by absorbance values at 562 nm; (c). The result of nuclear staining of two colon cancer cells treated with different doses by DAPI; (d). Changes in cell migration within 24 h; (e). Transwell experiment results; (f). Quantitative statistical results of cell migration experiments; G. Transwell experiment to quantify statistical results. ‘*’ indicates a significant difference compared with the control group (P < 0.05). ‘**’ indicates a significant difference (P < 0.01), the same below

Figure 2. Ropivacaine promoted apoptosis of colorectal cancer cells. (a). Flow cytometry to detect apoptosis results; (b). Quantitative graph of apoptosis ratio by flow cytometry to detect apoptosis results; (c). Immunoblotting to detect the expression of apoptosis-related proteins; (d). Quantification of immunoblotting results

Figure 2. Ropivacaine promoted apoptosis of colorectal cancer cells. (a). Flow cytometry to detect apoptosis results; (b). Quantitative graph of apoptosis ratio by flow cytometry to detect apoptosis results; (c). Immunoblotting to detect the expression of apoptosis-related proteins; (d). Quantification of immunoblotting results

Figure 3. Targeting relationship between ropivacaine and ITGB1 protein. (a). Immunoblotting to detect the expression of ITGB1 protein; (b). Quantitative graph of immunoblotting results; (c). Immunofluorescence detection of the distribution and expression of ITGB1 protein in cells; (d). Bioinformatics predicts the steric binding site of ropivacaine and ITGB1 protein

Figure 3. Targeting relationship between ropivacaine and ITGB1 protein. (a). Immunoblotting to detect the expression of ITGB1 protein; (b). Quantitative graph of immunoblotting results; (c). Immunofluorescence detection of the distribution and expression of ITGB1 protein in cells; (d). Bioinformatics predicts the steric binding site of ropivacaine and ITGB1 protein

Figure 4. Ropivacaine inhibited the expression of ITGB1 protein and affected the activation of its downstream signaling pathway. (a). Western blot detection of the downstream pathway of ITGB1 protein; (b). Quantification of Western blot detection results

Figure 4. Ropivacaine inhibited the expression of ITGB1 protein and affected the activation of its downstream signaling pathway. (a). Western blot detection of the downstream pathway of ITGB1 protein; (b). Quantification of Western blot detection results
Supplemental material

Supplemental Material

Download ()

Supplemental Material

Download ()

Supplemental Material

Download ()

Data availability statement

The datasets used or/and analyzed during the current study are available from the corresponding author on reasonable request.